Voyager Therapeutics
Develops CNS gene therapies and antibodies around TRACER delivery and tau biology.
$3.53
After-hours close−0.01 (−0.28%)
At close$3.54(+2.31%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 55.47%33.52M sharesInsiders 2.05%1.24M sharesOther 42.48%25.66M shares
Shares outstanding 60.42M · Float 50.40M · 83.4% free float
Institutions13F, as of Mar 31, 2026
139 holders · 33.52M shares · 28 new positions · 73 increased · 37 reduced · 18 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 5.57M | 9.22% | −50.0K | May 13, 2026 |
| Armistice Capital, LLC | 3.50M | 5.79% | −500.0K | May 15, 2026 |
| Millennium Management LLC | 3.43M | 5.67% | +1.55M | May 15, 2026 |
| Vestal Point Capital, LP | 3.00M | 4.97% | +1.53M | May 15, 2026 |
| Vanguard Capital Management LLC | 2.28M | 3.78% | +2.28Mnew | May 15, 2026 |
| Opaleye Management Inc. | 1.15M | 1.90% | −46.9K | May 15, 2026 |
| Erste Asset Management GmbH | 1.10M | 1.81% | −100.0K | May 11, 2026 |
| Geode Capital Management, LLC | 1.05M | 1.74% | −85.2K | May 15, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Armistice Capital, LLC | 8.65% | 4.80M | 13G | Aug 14, 2025 ↗ |
| BlackRock, Inc. | 6.40% | 3.53M | 13G | Apr 24, 2025 ↗ |
| Integrated Core Strategies (US) LLC | 6.00% | 3.34M | 13G | Jan 26, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Alfred Sandrock | director, officer: President and CEO | 472.5K | 0.78% | Apr 3, 2026 |
| Robin Swartz | officer: COO & CBO | 199.7K | 0.33% | Feb 26, 2026 |
| Toby Ferguson | officer: Chief Medical Officer | 183.9K | 0.30% | Feb 10, 2026 |
| Nathan D. Jorgensen | officer: Chief Financial Officer | 151.4K | 0.25% | Feb 26, 2026 |
| Todd Alfred Carter | officer: Chief Scientific Officer | 145.7K | 0.24% | Feb 26, 2026 |
| Gregory L. Shiferman | officer: SVP and General Counsel | 50.0K | 0.08% | Apr 3, 2026 |
| Amy Quinlan | officer: Principal Accounting Officer | 36.7K | 0.06% | May 18, 2026 |
4 ten-percent owners hold 14.71M shares by Form 4, outside the officers-and-directors figure above · 18 people have not refiled in the last 18 months (17.93M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Apr 2, 2026 | Alfred Sandrockdirector, officer: President and CEO | Sale | 11,511 | $3.87 | 472,549 |
| Feb 24, 2026 | Todd Alfred Carterofficer: Chief Scientific Officer | Sale | 4,174 | $3.76 | 145,718 |
| Feb 24, 2026 | Nathan D. Jorgensenofficer: Chief Financial Officer | Sale | 4,668 | $3.77 | 151,416 |
| Feb 24, 2026 | Alfred Sandrockdirector, officer: President and CEO | Sale | 14,197 | $3.79 | 484,060 |
| Feb 24, 2026 | Robin Swartzofficer: COO & CBO | Sale | 6,458 | $3.77 | 199,738 |
| Feb 18, 2026 | Alfred Sandrockdirector, officer: President and CEO | Sale | 11,732 | $3.41 | 498,257 |
| Feb 18, 2026 | Todd Alfred Carterofficer: Chief Scientific Officer | Sale | 3,301 | $3.44 | 149,892 |
| Feb 18, 2026 | Robin Swartzofficer: COO & CBO | Sale | 3,882 | $3.44 | 206,196 |
| Feb 10, 2026 | Todd Alfred Carterofficer: Chief Scientific Officer | Sale | 3,525 | $3.85 | 153,193 |
| Feb 10, 2026 | Alfred Sandrockdirector, officer: President and CEO | Sale | 12,192 | $3.78 | 509,989 |
CongressHouse and Senate disclosures
Not reported.